Collegium Pharmaceutical, Inc. (NASDAQ: NASDAQ: COLL ), a pharmaceutical company with a market capitalization of $928 million and impressive gross profit margins of 87%, has announced significant changes to its board of directors and executive team. According to InvestingPro analysis, the company is currently trading below its Fair Value, with analysts maintaining a bullish outlook. The company, a player in the pharmaceutical preparations industry, is preparing for its 2025 Annual Meeting of Shareholders with a focus on board refreshment and succession planning. Dr. Carlos Paya has been nominated to stand for election at the upcoming Annual Meeting. Dr. Paya brings extensive experience from the biopharma sector, including leadership roles at Vaxcyte, Inc., Highlight Therapeutics S.L, and Immune Design Corp. His nomination comes as part of the board's strategic refreshment initiative at a time when the company maintains strong financial health, with EBITDA reaching $369 million in the last twelve months.